Molecular Therapy Oncology

Molecular Therapy Oncology is an open access peer-reviewed journal published by Cell Press since 2023 under the eISSN 2950-3299 as a sister title to Molecular Therapy, covering oncology and gene and cell therapy for cancer with a 2025 Journal Impact Factor of 8.5 and first quartile ranks of 22 of 191 in medicine research and experimental and 40 of 333 in oncology in the Science Citation Index Expanded《分子肿瘤治疗》（Molecular Therapy Oncology）是（Cell Press）自 2023 年起出版的开放获取同行评审期刊，电子刊号 2950-3299，为《分子治疗》（Molecular Therapy）的姊妹刊，覆盖肿瘤学及肿瘤基因与细胞治疗，2025 年影响因子为 8.5，在（SCIE）医学研究与实验类 191 种期刊中列第 22 位、在肿瘤学类 333 种期刊中列第 40 位，均居第一四分位。

Scope

• The journal publishes original research, reviews and perspectives on molecular and cellular therapy for cancer, including gene therapy, cell therapy, oncolytic viruses, nucleic acid therapeutics and combination immunotherapy该刊刊载肿瘤分子与细胞治疗领域的原创研究、综述与观点，涉及基因治疗、细胞治疗、溶瘤病毒、核酸治疗药物以及联合免疫治疗等方向。
• It gives particular attention to translational and clinical studies that advance therapy from preclinical models to patient care, and it welcomes interdisciplinary work linking molecular therapy with oncology, immunology and drug delivery该刊特别关注将治疗从临床前模型推向患者照护的转化与临床研究，并欢迎分子治疗与肿瘤学、免疫学及药物递送交叉的研究。
• Article types include research articles, reviews, brief reports, perspectives and correspondence, and the journal operates a continuous publication model with articles assigned to a single annual volume文章类型包括研究论文、综述、简报、观点与通信，该刊采用连续出版模式，文章归入单一年度卷。
• As an open access journal it applies a Creative Commons attribution licence to accepted articles and levies an article processing charge on the corresponding author, with waivers available for qualifying authors作为开放获取期刊，该刊对录用文章采用知识共享署名许可，向通讯作者收取文章处理费，并对符合条件的作者提供减免。
• Peer review is conducted single-blind and the journal follows the Cell Press editorial policies on data availability, research integrity and competing interests同行评审采用单盲方式，该刊遵循（Cell Press）关于数据可获取性、研究诚信与利益冲突的编辑政策。
• The journal is abstracted and indexed in the Science Citation Index Expanded, Scopus, PubMed and MEDLINE, and it is included in the Journal Citation Reports from the 2024 edition onwards该刊被（SCIE）、（Scopus）、（PubMed）与（MEDLINE）收录，并自 2024 年版起纳入期刊引证报告。

History

• The journal was launched in 2023 by Cell Press as a companion to the long-running Molecular Therapy title, which was founded in 2000 by the American Society of Gene and Cell Therapy该刊于 2023 年由（Cell Press）创办，作为自 2000 年起由美国基因与细胞治疗学会主办的《分子治疗》刊的姊妹刊。
• It was conceived to provide a dedicated venue for oncology-focused molecular therapy research as the parent title broadened its scope, and its founding editorial board drew members from cancer centres and gene therapy programmes worldwide该刊定位为在母刊扩展范围之际为聚焦肿瘤的分子治疗研究提供专门平台，首届编委来自世界各地癌症中心与基因治疗项目。
• From its first year the journal operated as a gold open access title with a Creative Commons licence, and it has retained the continuous publication model since launch自创刊起该刊即为金色开放获取期刊，采用知识共享许可，并一直沿用连续出版模式。
• The Journal Impact Factor was first reported as 5.3 in 2024 and rose to 8.5 in 2025, placing the journal in the first quartile of both medicine research and experimental and oncology该刊的影响因子在 2024 年版首报 5.3，2025 年版升至 8.5，居医学研究与实验及肿瘤学两类第一四分位。
• The publisher carries the journal on the Cell Press platform and the digital object identifier prefix of its articles is 10.1016, shared with other Cell Press and Elsevier life science journals出版方将该刊载于（Cell Press）平台，其文章的数字对象唯一标识符前缀为（10.1016），与（Cell Press）及（Elsevier）其他生命科学期刊一致。

Editors

• The journal is led by an editor-in-chief supported by an international editorial board whose members are drawn from cancer research centres, medical schools and gene and cell therapy programmes across the world该刊由一位主编带领，配以由世界各地癌症研究中心、医学院及基因与细胞治疗项目学者组成的国际编委会。
• The editorial board includes section editors responsible for subject areas such as gene therapy, cell therapy, oncolytic virology and cancer immunotherapy, reflecting the molecular therapy scope of the journal编委会设有学科编辑，分别负责基因治疗、细胞治疗、溶瘤病毒学与肿瘤免疫治疗等方向，对应刊物的分子治疗定位。
• Editorial handling follows the Cell Press editorial management system, with submissions assigned to handling editors based on subject expertise and competing interest declarations稿件处理依托（Cell Press）的编辑管理系统，依据学科专长与利益冲突声明分配责任编辑。
• Peer review is conducted single-blind and the journal maintains the Cell Press standards on reviewer recruitment, conflict of interest management, data sharing and editorial independence同行评审采用单盲方式，该刊遵循（Cell Press）在审稿人遴选、利益冲突管理、数据共享与编辑独立性方面的标准。
• The masthead and board roster are published on the journal page at Cell Press and updated as new members join or existing members step down编委名单在（Cell Press）期刊页公布，并随成员增减而更新。